Navigation Links
DNA Engine Dyad Thermal Cycler Chassis, w/2 x 384-well blocks from Bio-Rad

ProductsDNA Engine Dyad Thermal Cycler Chassis, w/2 x 384-well blocks from Bio-Rad
Company Bio-Rad
Item DNA Engine Dyad Thermal Cycler Chassis, w/2 x 384-well blocks
Price 
Description The DNA Engine Dyad instrument is the most advanced thermal cycler ever made. Featuring MJ's world-class thermal performance, the Dyad also boasts graphical programming and color display, as well as point-and-click navigation via touch pad or mouse. The Dyad can be easily and economically expanded to a four-bay system with the addition of a Dyad Disciple thermal cycler.
Info Bio-RadBio-Rad
Bio-Rad Laboratories, Inc.
Life Science Research Group
2000 Alfred Nobel Drive
Hercules, CA 94547
USA
Customer Service: 800-424 6723
Fax Number: 800-879 2289
Web Site: http://discover.bio-rad.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. DNA Engine Opticon Continuous Fluorescence Detection System from Bio-Rad
2. DNA Engine Opticon Real-Time PCR Detection System from Bio-Rad
3. DNA Engine Thermal Cycler Chassis w/384-well block & motorized lid from Bio-Rad
4. DNA Engine Thermal Cycler Chassis, w/384-well block from Bio-Rad
5. DNA Engine Dyad Thermal Cycler Chassis from Bio-Rad
6. DNA Engine Tetrad 2 Thermal Cycler Chassis from Bio-Rad
7. DNA Engine Tetrad 2 Peltier Thermal Cycler, w/4 x 384-well blocks from Bio-Rad
8. DNA Engine Tetrad 2 Peltier Thermal Cycler from Bio-Rad
9. DNA Engine Tetrad 2 Peltier Thermal Cycler from Bio-Rad
10. DNA Engine Tetrad 2 Peltier Thermal Cycler, w/4 x 384-well blocks & motorized lid from Bio-Rad
11. DNA Engine Opticon 2 Continuous Fluorescence Detection System from Bio-Rad
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
... Nikon's Digital Sight DS-L2 imaging controller ... Imaging Controller DS-L1, and allows users to ... second generation DS-L2 controller features an 8.4 ... to a variety of Nikon cameras including ...
Biology Products:
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/22/2017)... Feb. 22, 2017 With the biometrics ... Research identifies four technologies that innovative and agile ... significant share in the changing competitive landscape: multifactor ... authentication.   "Companies can no longer ... security," says Dimitrios Pavlakis , Industry Analyst ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
Breaking Biology News(10 mins):
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology: